证券代码：000403 证券简称：派林生物 派斯双林生物制药股份有限公司投资者关系活动记录表 编号：【2025】002 | | □特定对象调研 □ 分析师会议 | | --- | --- | | 投资者关系活 | □媒体采访☑业绩说明会 | | | □新闻发布会 □路演活动 | | 动类别 | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称 | 通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | 及人员姓名 | 络远程的方式召开业绩说明会提问的投资者 | | 时间 | 2025 年 5 月 20 日 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | 用网络远程的方式召开业绩说明会 | | 上市公司接待 | 总经理 荣先奎 | | | 董事会秘书赵玉林 | | 人员姓名 | 财务总监 王晔弘 | | | 主要问答记录如下： | | | 1、请问陕煤集团对公司的战略定位？公司在争取陕煤集团支持 | | | 和赋能方面有哪些举措和成效？ | | 投资者关系活 | 公司将聚焦血液制品主业， ...

Industry Outlook - The blood products industry in China is expected to maintain high growth due to factors such as improved consumption structure, enhanced plasma utilization, normalized exports, and increased government support [1] - The market capacity for blood products is projected to exceed 100 billion RMB in the future [2] Company Performance - In 2024, the company reported a revenue of 2.655 billion RMB, a year-on-year increase of 14%, and a net profit of 745 million RMB, up 21.76% [4] - The net profit margin for 2024 was 28.07%, reflecting a year-on-year increase of 1.81 percentage points [5] Production and Capacity - The company’s plasma collection volume in 2024 exceeded 1,100 tons, with an expected increase to over 1,400 tons in 2025, representing a growth of over 20% [5][6] - Post-expansion, the annual production capacity is anticipated to exceed 3,000 tons [6][8] Growth Strategies - The company plans to increase the number of plasma collection stations through both organic growth and acquisitions [3] - Continuous R&D efforts will be made to enhance product variety and improve profit margins per ton of plasma [3] Market Position - The overall performance of the blood products industry is strong, with the company positioned favorably compared to peers [4] - The company has received over 10 county-level and 5 city-level approvals for new plasma stations, aiming for significant expansion in 2025 [7] Future Projections - The company aims to maintain double-digit profit growth in 2025 [6] - The fourth-generation intravenous immunoglobulin is expected to be approved in the first half of 2027 [8] Shareholder Engagement - The company has implemented a value management system and is actively pursuing share buyback plans, maintaining a high dividend payout ratio [10]